

## PRIOR AUTHORIZATION POLICY

- POLICY:** Inflammatory Conditions – Infliximab Products Prior Authorization Policy
- Avsola™ (infliximab-axxq intravenous infusion – Amgen)
  - Inflectra® (infliximab-dyyb intravenous infusion – Hospira/Pfizer)
  - Infliximab intravenous infusion – Janssen/Johnson & Johnson
  - Remicade® (infliximab intravenous infusion – Janssen/Johnson & Johnson)
  - Renflexis® (infliximab-abda intravenous infusion – Samsung Bioepis/Merck)

**REVIEW DATE:** 09/29/2021; selected revision 12/08/2021

---

### OVERVIEW

Infliximab products are tumor necrosis factor inhibitors (TNFis) approved for the following indications:<sup>1-3</sup>

- **Ankylosing spondylitis**, for reducing signs and symptoms of active disease.
- **Crohn's disease**, for the following uses:
  - Reducing the signs and symptoms and inducing and maintaining clinical remission in patients  $\geq 6$  years of age with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy; AND
  - Reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adults with fistulizing Crohn's disease.
- **Plaque psoriasis**, for treatment of adults with chronic severe (i.e., extensive and/or disabling) disease who are candidates for systemic therapy and when other systemic therapies are less appropriate.
- **Psoriatic arthritis**, for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage and improving physical function.
- **Rheumatoid arthritis**, in combination with methotrexate for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active disease.
- **Ulcerative colitis**, for the following uses:
  - Reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adults with moderately to severely active disease who have had an inadequate response to conventional therapy; AND
  - Reducing signs and symptoms and inducing and maintaining clinical remission in patients  $\geq 6$  years of age with moderately to severely active disease who have had an inadequate response to conventional therapy.

Avsola, Inflectra, and Renflexis were approved as biosimilar to Remicade, indicating no clinically meaningful differences in safety and effectiveness and the same mechanism of action, route of administration, dosage form, and strength as Remicade.<sup>2-3</sup> However, minor differences in clinically inactive components are allowed. At this time, only biosimilarity has been demonstrated (not interchangeability).

### Guidelines

TNFis feature prominently in guidelines for treatment of many inflammatory conditions.

- **Crohn's Disease:** The American College of Gastroenterology (ACG) has guidelines for Crohn's disease (2018).<sup>4</sup> TNFis are listed as an option for disease that is resistant to corticosteroids, severely active disease, perianal fistulizing disease, and maintenance of remission. In post-operative Crohn's disease, a TNFi should be started within 4 weeks of surgery to prevent recurrence. Guidelines from the American Gastroenterological Association (AGA) [2021] include infliximab

among the therapies for moderate to severe Crohn's disease, for induction and maintenance of remission.<sup>5</sup>

- **Plaque Psoriasis:** Guidelines from the American Academy of Dermatologists (AAD) and National Psoriasis Foundation (NPF) [2019] recommend infliximab as a monotherapy treatment option for adults with moderate to severe disease.<sup>6</sup>
- **Psoriatic Arthritis:** Guidelines from the American College of Rheumatology (ACR) [2019] recommend TNFis over other biologics for use in treatment-naïve patients with psoriatic arthritis, and in those who were previously treated with an oral therapy.<sup>7</sup>
- **Rheumatoid Arthritis:** Guidelines from the ACR (2021) recommend addition of a biologic or a targeted synthetic disease modifying anti-rheumatic drug (DMARD) for a patient taking the maximum tolerated dose of methotrexate who is not at target.<sup>8</sup>
- **Spondyloarthritis:** Guidelines for ankylosing spondylitis and non-radiographic axial spondyloarthritis are published by ACR/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network (2019).<sup>9</sup> Following primary nonresponse to a TNFi, an interleukin (IL)-17 blocker is recommended; however, if the patient is a secondary nonresponder, a second TNFi is recommended over switching out of the class. In patients with a contraindication to a TNFi, use of an IL-17 blocker is recommended over traditional oral agents such as methotrexate or sulfasalazine.
- **Ulcerative Colitis:** Updated ACG guidelines for ulcerative colitis (2019) note that the following agents can be used for induction of remission in moderately to severely active disease: budesonide extended-release tablets; oral or intravenous systemic corticosteroids, Entyvio<sup>®</sup> (vedolizumab intravenous infusion), Xeljanz<sup>®</sup>/XR (tofacitinib tablets/extended-release tablets), or TNFis.<sup>10</sup> In addition to the approved indication, clinical guidelines for the management of pouchitis, published in 2009 indicate that first-line therapy for pouchitis is antibiotic therapy (e.g. metronidazole, ciprofloxacin).<sup>11</sup> Other treatment options include maintenance probiotics, oral or topical budesonide, anti-inflammatory drugs (e.g., mesalamine), or immunosuppressive drugs (e.g., infliximab). Guidelines from the AGA (2020) recommend infliximab for moderate to severe ulcerative colitis.<sup>12</sup>

#### *Other Uses with Supportive Evidence*

There are guidelines and/or published data supporting the use of infliximab products in the following conditions:

- **Behcet's Disease:** The European League Against Rheumatism (EULAR) recommendations (2018) include TNFis for initial or recurrent sight-threatening uveitis.<sup>13</sup> For patients refractory to first-line treatments (e.g., corticosteroids), TNFis are among the treatment options for mucocutaneous manifestations, venous thrombosis, severe or refractory gastrointestinal disease, and recurrent/chronic joint involvement. Recommendations for the use of TNFis in ocular inflammatory disorders from the American Academy of Ophthalmology (AAO) [2014] note that TNFis may be used first-line in patients with ophthalmic manifestations of Behcet's disease and for acute exacerbations of pre-existing Behcet's disease.<sup>14</sup>
- **Graft-Versus-Host Disease:** Guidelines from the National Comprehensive Cancer network (NCCN) [version 4.2021 – September 9, 2021] list infliximab among the agents used for steroid-refractory disease.<sup>15</sup>
- **Hidradenitis Suppurativa:** In a Phase II double-blind, placebo-controlled crossover trial, adult patients with moderate to severe hidradenitis suppurativa were randomized to placebo (n = 23) or infliximab 5 mg/kg (n = 15) at Weeks 0, 2, and 6.<sup>16</sup> Maintenance was continued through 22 weeks of treatment. Following Week 8, more patients in the infliximab-treatment group experienced a 50% or greater decrease in the Hidradenitis Suppurativa Severity Index (HSSI) score (approximately 26% and 5% of patients receiving infliximab and placebo, respectively [data presented graphically]; P = 0.092). In post-hoc analysis, significantly more patients treated with

infliximab responded with a 25% to < 50% response (60% and 5.6% for infliximab and placebo, respectively;  $P < 0.001$ ). Improvement was noted through Week 30. In case series, infliximab has been effective in treating hidradenitis suppurativa that was refractory to other therapies.<sup>17-19</sup>

- **Immunotherapy-Related Toxicities Associated with Checkpoint Inhibitors:** NCCN has guidelines (version 3.2021 – May 14, 2021) for Management of Immunotherapy-Related Toxicities.<sup>20</sup> Infliximab is recommended to manage inflammatory arthritis, vision changes, myocarditis, pericarditis, inflammatory arthritis, acute kidney injury (e.g., azotemia, creatinine elevation, inability to maintain acid/base or electrolyte balance, urine output change), pneumonitis, myalgia, or myositis, and diarrhea/colitis. Additionally, the guidelines also note that infliximab should not be used to treat hepatitis associated with an immunotherapy-related toxicity.
- **Indeterminate Colitis:** Infliximab has been effective in some patients with refractory indeterminate colitis (retrospective reviews).<sup>21,22</sup> When patients who are refractory to standard therapy can be definitively classified as having ulcerative colitis, colectomy is considered an effective long-term surgical treatment. Patient's with Crohn's disease, however, have a high risk of complications after ileal pouch-anal anastomosis and are treated more aggressively with medical interventions since surgical options cannot offer the same likelihood of success as in ulcerative colitis.
- **Juvenile Idiopathic Arthritis (JIA):** The ACR/Arthritis Foundation Guideline for the treatment of JIA (2019) provides updated recommendations for juvenile non-systemic polyarthritis, sacroiliitis, and enthesitis.<sup>23</sup> Infliximab is among the TNFis recommended as subsequent therapy following treatment with a conventional synthetic DMARD such as methotrexate. TNF antagonists such as infliximab may also be used as second- or third-line treatment for systemic JIA.<sup>24</sup>
- **Ocular Inflammatory Disorders:** Recommendations for the use of TNFis in ocular inflammatory disorders from the AAO (2014) note that infliximab may be used as second-line corticosteroid-sparing therapy for chronic and severe scleritis.<sup>14</sup> Infliximab may be used in patients with uveitis due to various causes (e.g., spondyloarthritis-associated or human leukocyte antigen [HLA]-B27-associated uveitis, juvenile idiopathic arthritis-associated uveitis, and other posterior uveitides and panuveitis syndromes). Infliximab should be considered second-line in vision-threatening JIA-associated uveitis when methotrexate has failed or is not tolerated (strong recommendation) and vision-threatening chronic uveitis from seronegative spondyloarthritis (strong recommendation). Infliximab may also be considered in other patients who have vision-threatening or corticosteroid-dependent disease who have failed first-line therapies. The recommendations point out that studies evaluating infliximab in uveitis included patients with birdshot chorioretinitis (BSCR), a bilateral posterior uveitis generally treated with systemic immunomodulation; these patients showed a good response to infliximab.
- **Pyoderma Gangrenosum:** Although guidelines are not current, multiple topical and systemic therapies have been used for pyoderma gangrenosum. Oral prednisone is the most common initial immunosuppressant medication.<sup>25</sup> Other systemic therapies include cyclosporine, methotrexate, azathioprine, cyclophosphamide, mycophenolate mofetil, and TNFis (i.e., infliximab, etanercept, and adalimumab products). In case reports, TNFis have been effective.
- **Sarcoidosis:** Recommendations for best practice in the management of pulmonary and systemic sarcoidosis recommend glucocorticoids as first-line therapy.<sup>26</sup> Patients who cannot be weaned to a prednisone-equivalent dose of < 10 mg/day are appropriate candidates for steroid-sparing treatment with cytotoxic agents (e.g., methotrexate, azathioprine, leflunomide). If these agents fail or cause toxicity, adalimumab, infliximab, cyclophosphamide, or mycophenolate mofetil are proposed.
- **Still's Disease:** Still's disease presents in adults with features similar to those of systemic onset JIA.<sup>27,28</sup> In case series, infliximab has been effective in patients with Still's disease that was refractory to therapy with corticosteroids, methotrexate, azathioprine, and cyclophosphamide.<sup>29</sup>

## **POLICY STATEMENT**

Prior Authorization is recommended for prescription benefit coverage of infliximab products. Because of the specialized skills required for evaluation and diagnosis of a patient treated with infliximab as well as the monitoring required for adverse events and long-term efficacy, initial approval requires infliximab to be prescribed by or in consultation with a physician who specializes in the condition being treated. All approvals are provided for the duration listed below. In cases where the approval is authorized in months, 1 month is equal to 30 days.

**Automation:** None.

## **RECOMMENDED AUTHORIZATION CRITERIA**

Coverage of infliximab products is recommended in those who meet one of the following criteria:

### **FDA-Approved Indications**

- 1. Ankylosing Spondylitis.** Approve for the duration noted if the patient meets ONE of the following (A or B):
  - A) Initial Therapy.** Approve for 3 months if prescribed by or in consultation with a rheumatologist.
  - B) Patient is Currently Receiving an Infliximab Product.** Approve for 1 year if the patient had a response as determined by the prescriber.

Note: Examples of a response to therapy include decreased pain or stiffness, improved function or activities of daily living. Patient may not have a full response, but there should have been a recent or past response to an infliximab product.
  
- 2. Crohn's Disease.** Approve for the duration noted if the patient meets ONE of the following (A or B):
  - A) Initial Therapy.** Approve for 3 months if the patient meets the following criteria (i, ii, and iii):
    - i.** Patient is  $\geq 6$  years of age; AND
    - ii.** Patient meets ONE of the following conditions (a, b, c, or d):
      - a)** Patient has tried or is currently taking corticosteroids, or corticosteroids are contraindicated in this patient; OR  
Note: Examples of corticosteroids are prednisone and methylprednisolone.
      - b)** Patient has tried one other conventional systemic therapy for Crohn's disease; OR  
Note: Examples of conventional systemic therapies for Crohn's disease include azathioprine, 6-mercaptopurine, or methotrexate. A previous trial of a biologic also counts as a trial of one other agent for Crohn's disease. Refer to Appendix for examples of biologics used for Crohn's disease.
      - c)** Patient has enterocutaneous (perianal or abdominal) or rectovaginal fistulas; OR
      - d)** Patient had ileocolonic resection (to reduce the chance of Crohn's disease recurrence); AND
    - iii.** The medication is prescribed by or in consultation with a gastroenterologist.
  - B) Patient is Currently Receiving an Infliximab Product.** Approve for 1 year if the patient had a response, as determined by the prescriber.

Note: Patient may not have a full response, but there should have been a recent or past response to an infliximab product.
  
- 3. Plaque Psoriasis.** Approve for the duration noted if the patient meets ONE of the following (A or B):
  - A) Initial Therapy.** Approve for 3 months if the patient meets the following criteria (i, ii, and iii):
    - i.** Patient is  $\geq 18$  years of age; AND
    - ii.** Patient meets ONE of the following conditions (a or b):

- a) Patient has tried at least one traditional systemic agent for psoriasis for at least 3 months, unless intolerant; OR  
Note: Examples include methotrexate, cyclosporine, acitretin (Soriatane<sup>®</sup>, generics), or psoralen plus ultraviolet A light (PUVA). An exception to the requirement for a trial of one traditional systemic agent for psoriasis can be made if the patient already had a 3-month trial or previous intolerance to at least one biologic. Refer to Appendix for examples of biologics used for psoriasis. A patient who has already tried a biologic for psoriasis is not required to “step back” and try a traditional systemic agent for psoriasis.
  - b) Patient has a contraindication to methotrexate, as determined by the prescriber; AND
  - iii. The medication is prescribed by or in consultation with a dermatologist.
  - B) Patient is Currently Receiving an Infliximab Product. Approve for 1 year if the patient had a response, as determined by the prescriber.  
Note: Patient may not have a full response, but there should have been a recent or past response to an infliximab product.
4. **Psoriatic Arthritis.** Approve for the duration noted if the patient meets ONE of the following (A or B):
- A) Initial Therapy. Approve for 3 months if prescribed by or in consultation with a rheumatologist or a dermatologist.
  - B) Patient is Currently Receiving an Infliximab Product. Approve for 1 year if the patient had a response as determined by the prescriber.  
Note: Examples of a response include less joint pain, morning stiffness, or fatigue; improved function or activities of daily living; decreased soft tissue swelling in joints or tendon sheaths; improvements in acute phase reactants (for example, C-reactive protein). Patient may not have a full response, but there should have been a recent or past response to an infliximab product.
5. **Rheumatoid Arthritis.** Approve for the duration noted if the patient meets ONE of the following (A or B):
- A) Initial Therapy. Approve for 3 months if the patient meets BOTH of the following criteria (i and ii):
    - i. Patient has tried ONE conventional synthetic disease-modifying antirheumatic drug (DMARD) for at least 3 months; AND  
Note: Examples include methotrexate (oral or injectable), leflunomide, hydroxychloroquine, and sulfasalazine. An exception to the requirement for a trial of one conventional synthetic DMARD can be made if the patient already had a 3-month trial of at least one biologic. Refer to Appendix for examples of biologics used for rheumatoid arthritis. A patient who has already tried a biologic is not required to “step back” and try a conventional synthetic DMARD.
    - ii. The medication is prescribed by or in consultation with a rheumatologist.
  - B) Patient is Currently Receiving an Infliximab Product. Approve for 1 year if the patient had a response as determined by the prescriber.  
Note: Examples of a response include less joint pain, morning stiffness, or fatigue; improved function or activities of daily living; decreased soft tissue swelling in joints or tendon sheaths; improved laboratory values; reduced dosage of corticosteroids. Patient may not have a full response, but there should have been a recent or past response to an infliximab product.
6. **Ulcerative Colitis.** Approve for the duration noted if the patient meets ONE of the following (A or B):
- A) Initial Therapy. Approve for 3 months if the patient meets the following criteria (i, ii, and iii):
    - i. Patient is  $\geq 6$  years of age; AND
    - ii. Patient meets ONE of the following conditions (a or b):
      - a) Patient had a trial of one systemic agent or was intolerant to one of these agents for ulcerative colitis; OR

Note: Examples include 6-mercaptopurine, azathioprine, cyclosporine, tacrolimus, or a corticosteroid such as prednisone or methylprednisolone. A previous trial of a biologic also counts as a trial of one systemic agent for ulcerative colitis. Refer to Appendix for examples of biologics used for ulcerative colitis.

**b)** Patient meets BOTH of the following [(1) and (2)]:

**(1)** Patient has pouchitis; AND

**(2)** Patient has tried therapy with an antibiotic, probiotic, corticosteroid enema, or Rowasa® (mesalamine enema); AND

Note: Examples of antibiotics include metronidazole and ciprofloxacin. Examples of corticosteroid enemas include hydrocortisone enema (Cortenema, generics).

**iii.** The medication is prescribed by or in consultation with a gastroenterologist.

**B) Patient is Currently Receiving an Infliximab Product.** Approve for 1 year if the patient had a response as determined by the prescriber.

Note: Examples of a response include decreased stool frequency or rectal bleeding. The patient may not have a full response, but there should have been a recent or past response to an infliximab product.

### Other Uses with Supportive Evidence

**7. Behcet’s Disease.** Approve for the duration noted if the patient meets ONE of the following criteria (A or B):

**A) Initial Therapy.** Approve for 3 months if the patient meets BOTH of the following conditions (i and ii):

**i.** Patient meets ONE of the following (a or b):

**a)** Patient has tried at least ONE conventional therapy; OR

Note: Examples include systemic corticosteroids (e.g., methylprednisolone), immunosuppressants (azathioprine, methotrexate, mycophenolate mofetil, cyclosporine, tacrolimus, Leukeran® [chlorambucil tablet], cyclophosphamide, interferon alfa). An exception to the requirement for a trial of one conventional therapy can be made if the patient has already had a trial of at least one tumor necrosis factor inhibitor (e.g., an adalimumab product, an etanercept product). A patient who has already tried a biologic for Behcet’s disease is not required to “step back” and try a conventional therapy.

**b)** Patient has ophthalmic manifestations of Behcet’s disease; AND

**ii.** The medication is prescribed by or in consultation with a rheumatologist, dermatologist, ophthalmologist, gastroenterologist, or neurologist.

**B) Patient is Currently Receiving an Infliximab Product.** Approve for 1 year if the patient had a response, as determined by the prescriber.

Note: Patient may not have a full response by Month 2 or 3, but there should be some response.

**8. Graft-Versus-Host Disease.** Approve for the duration noted if the patient meets ONE of the following criteria (A or B):

**A) Initial Therapy.** Approve for 1 month if the patient meets BOTH of the following (i and ii):

**i.** Patient has tried at least one conventional systemic treatment for graft-versus-host disease; AND

Note: Examples of conventional treatments include corticosteroids (e.g., methylprednisolone), antithymocyte globulin, cyclosporine, tacrolimus, and mycophenolate mofetil.

**ii.** The medication is prescribed by or in consultation with an oncologist, hematologist, or a physician affiliated with a transplant center; OR

**B) Patient is Currently Receiving an Infliximab Product.** Approve for 3 months if the patient had a response, as determined by the prescriber.

**9. Hidradenitis Suppurativa.** Approve for the duration noted if the patient meets ONE of the following criteria (A or B):

**A) Initial Therapy.** Approve for 3 months if the patient meets BOTH of the following (i and ii):

i. Patient has tried one other therapy; AND

Note: Examples include intralesional or oral corticosteroids (e.g., triamcinolone, prednisone), systemic antibiotics (e.g., clindamycin, dicloxacillin, erythromycin), and isotretinoin.

ii. The medication is prescribed by or in consultation with a dermatologist.

**B) Patient is Currently Receiving an Infliximab Product.** Approve for 1 year if the patient had a response, as determined by the prescriber.

**10. Immunotherapy-Related Toxicities Associated with Checkpoint Inhibitor Therapy.** Approve for the duration noted if the patient meets ONE of the following (A or B):

**A) Initial Therapy.** Approve for 3 months if the patient meets ALL of the following (i, ii, iii, and iv):

i. Patient developed an immunotherapy-related toxicity other than hepatitis; AND

Note: For example, gastrointestinal system toxicity (e.g., colitis), ocular toxicity (e.g., uveitis/iritis, episcleritis, and blepharitis), myocarditis, pericarditis, inflammatory arthritis, acute kidney injury (e.g., azotemia, creatinine elevation, inability to maintain acid/base or electrolyte balance, urine output change), pneumonitis, myalgia, or myositis.

ii. Patient developed this immune-related toxicity while receiving a checkpoint inhibitor; AND

Note: Examples of checkpoint inhibitors include Keytruda (pembrolizumab intravenous [IV] infusion), Opdivo (nivolumab IV infusion), Yervoy (ipilimumab IV infusion), Tecentriq (atezolizumab IV infusion), Bavencio (avelumab IV infusion), or Imfinzi (durvalumab IV infusion).

iii. Patient has tried one systemic corticosteroid; AND

Note: Examples include methylprednisone and prednisone.

iv. The medication is prescribed by or in consultation with an oncologist, gastroenterologist, rheumatologist, or ophthalmologist; OR

**B) Patient is Currently Receiving an Infliximab Product.** Approve for 1 year if the patient has responded and needs continued treatment, as determined by the prescriber.

**11. Indeterminate Colitis** (defined as colitis that cannot be classified with certainty as either ulcerative colitis or Crohn's disease). Approve for the duration noted if the patient meets ONE of the following (A or B):

**A) Initial Therapy.** Approve for 4 months if the patient meets ALL of the following (i, ii, iii, iv, and v):

i. Patient is  $\geq 6$  years of age; AND

ii. Patient has tried one systemic corticosteroid; AND

Note: Examples include prednisone and methylprednisolone.

iii. Patient has tried mesalamine; AND

iv. Patient has tried either azathioprine or 6-mercaptopurine; AND

v. The medication is prescribed by or in consultation with a gastroenterologist.

**B) Patient is Currently Receiving an Infliximab Product.** Approve for 1 year if the patient had a response, as determined by the prescriber.

**12. Juvenile Idiopathic Arthritis (JIA).** Approve for the duration noted if the patient meets ONE of the following (A or B):

Note: This includes JIA regardless of type of onset, including a patient with juvenile spondyloarthropathy/active sacroiliac arthritis. JIA is also referred to as Juvenile Rheumatoid Arthritis.

**A) Initial Therapy.** Approve for 3 months if the patient meets the following criteria (i and ii):

i. Patient meets ONE of the following conditions (a or b):

a) Patient has tried one other systemic medication for this condition; OR

Note: Examples of other medications for JIA include methotrexate, sulfasalazine, or leflunomide, a nonsteroidal anti-inflammatory drug (NSAID) [e.g., ibuprofen, naproxen]. A previous trial of a biologic also counts as a trial of one medication. Refer to Appendix for examples of biologics used for JIA.

- b) Patient has aggressive disease, as determined by the prescriber; AND
- ii. The medication is prescribed by or in consultation with a rheumatologist.
- B) Patient is Currently Receiving an Infliximab Product. Approve for 1 year if the patient had a response as determined by the prescriber.

Note: Examples of a response include improvement in limitation of motion, less joint pain or tenderness, decreased duration of morning stiffness or fatigue, improved function or activities of daily living, reduced dosage of corticosteroids. The patient may not have a full response, but there should have been a recent or past response to an infliximab product.

**13. Pyoderma Gangrenosum.** Approve for the duration noted if the patient meets ONE of the following criteria (A or B):

- A) Initial Therapy. Approve for 4 months if the patient meets BOTH of the following conditions (i and ii):
  - i. Patient meets ONE of the following conditions (a or b):
    - A) Patient has tried one systemic corticosteroid; OR
    - Note: Examples include prednisone and methylprednisolone.
    - B) Patient has tried one other immunosuppressant for at least 2 months or was intolerant to one of these medications; AND
    - Note: Examples include mycophenolate mofetil and cyclosporine.
  - ii. The medication is prescribed by or in consultation with a dermatologist.
- B) Patient is Currently Receiving an Infliximab Product. Approve for 1 year if the patient had a response, as determined by the prescriber.
- Note: Patient may not have a full response by Month 4 or 5 (after 4 doses), but there should be some response.

**14. Sarcoidosis.** Approve for the duration noted if the patient meets ONE of the following criteria (A or B):

- A) Initial Therapy. Approve for 3 months if the patient meets ALL of the following conditions (i, ii, and iii):
  - i. Patient has tried at least one corticosteroid; AND
  - Note: Examples include prednisone and methylprednisolone.
  - ii. Patient has tried at least one immunosuppressive medication; AND
  - Note: Examples include methotrexate, azathioprine, cyclosporine, Leukeran<sup>®</sup> (chlorambucil tablet), Thalomid<sup>®</sup> (thalidomide capsules), or chloroquine.
  - iii. The medication is prescribed by or in consultation with a pulmonologist, ophthalmologist, or dermatologist; OR
- B) Patient is Currently Receiving an Infliximab Product. Approve for 1 year if the patient had a response, as determined by the prescriber.
- Note: The patient may not have a full response by Month 3, but there should be some response.

**15. Scleritis or Sterile Corneal Ulceration.** Approve for the duration noted if the patient meets ONE of the following criteria (A or B):

- A) Initial Therapy. Approve for 3 months if the patient meets BOTH of the following conditions (i and ii):
  - i. Patient has tried one other therapy for this condition; AND



Note: Examples include oral non-steroidal anti-inflammatory drugs (NSAIDs) such as indomethacin; oral, topical (ophthalmic) or intravenous corticosteroids (such as prednisone, prednisolone, methylprednisolone); methotrexate; cyclosporine; or other immunosuppressants.

ii. The medication is prescribed by or in consultation with an ophthalmologist.

**B) Patient is Currently Receiving an Infliximab Product.** Approve for 1 year if the patient had a response as determined by the prescriber.

Note: Examples of a response to therapy include decreased inflammation, reduced use of steroids or immunomodulators, decreased eye pain, redness, and/or photophobia. The patient may not have a full response by Month 2 or 3, but there should be some response.

**16. Spondyloarthritis, Other Subtypes.** Approve for the duration noted if the patient meets ONE of the following criteria (A or B):

Note: Examples of other subtypes include undifferentiated arthritis, non-radiographic axial spondylitis, Reactive Arthritis (Reiter’s disease). For ankylosing spondylitis or psoriatic arthritis, refer to the respective criteria under FDA-approved indications.

**A) Initial Therapy.** Approve for 3 months if the patient meets BOTH of the following conditions (i and ii):

i. Patient meets ONE of the following (a or b):

a) Patient has arthritis primarily in the knees, ankles, elbows, wrists, hands, and/or feet AND has tried at least ONE conventional synthetic disease-modifying antirheumatic drug (DMARD); OR

Note: Examples include methotrexate, leflunomide, and sulfasalazine.

b) Patient has axial spondyloarthritis with objective signs of inflammation, defined as at least one of the following [(1) or (2)]:

(1) C-reactive protein elevated beyond the upper limit of normal for the reporting laboratory; OR

(2) Sacroiliitis reported on magnetic resonance imaging; AND

ii. The medication is prescribed by or in consultation with a rheumatologist; OR

**B) Patient is Currently Receiving an Infliximab Product.** Approve for 1 year if the patient had a response as determined by the prescriber.

Note: Examples of a response include decreased pain or stiffness, improved function or activities of daily living. The patient may not have a full response, but there should have been a recent or past response to an infliximab product.

**17. Still’s Disease.** Approve for the duration noted if the patient meets ONE of the following criteria (A or B):

**A) Initial Therapy.** Approve for 3 months if the patient meets ALL of the following (i, ii, and iii):

i. Patient has tried one corticosteroid; AND

Note: Examples include prednisone and methylprednisolone.

ii. Patient has tried one conventional synthetic disease-modifying antirheumatic drug (DMARD) given for at least 2 months or was intolerant; AND

Note: An example is methotrexate.

iii. The medication is prescribed by or in consultation with a rheumatologist.

**B) Patient is Currently Receiving an Infliximab Product.** Approve for 1 year if the patient had a response, as determined by the prescriber.

Note: Patient may not have a full response by Month 2 or 3, but there should be some response.

**18. Uveitis.** Approve for the duration noted if the patient meets ONE of the following criteria (A or B):

Note: This includes other posterior uveitides and panuveitis syndromes.

**A) Initial Therapy.** Approve for 3 months if the patient meets BOTH of the following conditions (i and ii):

- i. Patient has tried one of the following therapies: periocular, intraocular, or systemic corticosteroids, or immunosuppressives; AND

Note: Examples of corticosteroids include prednisolone, triamcinolone, betamethasone, methylprednisolone, prednisone. Examples of immunosuppressives include methotrexate, mycophenolate mofetil, and cyclosporine. An exception to the requirement for a trial of one of these therapies can be made if the patient has already had a trial of an etanercept product or an adalimumab product for uveitis. A patient who has already tried a biologic for uveitis is not required to try another medication.

- ii. The medication is prescribed by or in consultation with an ophthalmologist.

- B) Patient is Currently Receiving an Infliximab Product.** Approve for 1 year if the patient had a response as determined by the prescriber.

Note: Examples of a response include decreased inflammation, reduced use of steroids or immunomodulators, and improvement in visual acuity. The patient may not have a full response by Month 2 or 3, but there should be some response.

### CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of infliximab products is not recommended in the following situations:

- 1. Concurrent Use with a Biologic or with a Targeted Synthetic Disease-Modifying Antirheumatic Drug (DMARD).** Data are lacking evaluating concomitant use of an infliximab product in combination with another biologic or with a targeted synthetic DMARD used for an inflammatory condition (see [APPENDIX](#) for examples). Combination therapy with biologics and/or biologics + targeted synthetic DMARDs has a potential for a higher rate of AEs and lack controlled trial data in support of additive efficacy.  
Note: This does NOT exclude the use of conventional synthetic DMARDs (e.g., methotrexate, leflunomide, hydroxychloroquine, and sulfasalazine) in combination with an infliximab product.
- 2. Inflammatory Myopathies (Polymyositis, Dermatomyositis, Inclusion Body Myositis).** Exceptions are not recommended. In an open-label pilot study in 13 patients, four infliximab 5 mg/kg infusions given over 14 weeks were not effective in refractory inflammatory myopathies.<sup>30</sup> Infliximab could worsen muscle inflammation in these patients.
- 3. Large Vessel Vasculitis (e.g., Giant Cell Arteritis, Takayasu's Arteritis).** Guidelines from EULAR for the management of large vessel vasculitis (e.g., giant cell arteritis, Takayasu's arteritis) recommend corticosteroids as first line therapy for giant cell arteritis.<sup>31</sup> For Takayasu's arteritis, corticosteroids and conventional synthetic DMARDs are listed as first-line therapy.
- 4.** Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

### REFERENCES

1. Remicade injection [prescribing information]. Horsham, PA: Janssen; December 2021.
2. Inflectra injection [prescribing information]. Lake Forest, IL: Hospira/Pfizer; June 2021.
3. Renflexis injection [prescribing information]. Whitehouse Station, NJ: Samsung Bioepis/Merck; June 2019.
4. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol.* 2018;113(4):481-517.
5. Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. *Gastroenterology.* 2021;160(7):2496-2508.
6. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol.* 2019;80(4):1029-1072.

7. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis. *Arthritis Care Res (Hoboken)*. 2019;71(1):2-29.
8. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Rheumatol*. 2021;73(7):1108-1123.
9. Ward MM, Deodhar A, Gensler LS, et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. *Arthritis Rheumatol*. 2019;(10):1599-1613.
10. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. *Am J Gastroenterol*. 2019;114(3):384-413.
11. Pardi DS, D'Haens G, Shen B, et al. Clinical guidelines for the management of pouchitis. *Inflamm Bowel Dis*. 2009;15(9):1424-1431.
12. Feuerstein JD, Isaac s KL, Schneider Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. *Gastroenterology*. 2020;158:1450-1461.
13. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet's syndrome. *Ann Rheum Dis*. 2018;77(6):808-818.
14. Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. *Ophthalmology*. 2014;121(3):785-796.
15. The NCCN Hematopoietic Cell Transplantation (HCT): pre-transplant recipient evaluation and management of graft versus host disease Clinical Practice Guidelines in Oncology (Version 2.2021 – September 9, 2021). © 2021 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on September 24, 2021.
16. Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. *J Am Acad Dermatol*. 2010;62(2):205-217.
17. Sullivan TP, Welsh E, Kerdel FA, et al. Infliximab for hidradenitis suppurativa. *Br J Dermatol*. 2003;149:1046-1049.
18. Fardet L, Dupuy A, Kerob D, et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. *J Am Acad Dermatol*. 2007;56:624-628.
19. Haslund P, Lee RA, Jemec GB. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors. *Acta Derm Venereol*. 2009;89(6):595-600.
20. Papadakis KA, Treyzon L, Abreu MT, et al. Infliximab in the treatment of medically refractory indeterminate colitis. *Aliment Pharmacol Ther*. 2003;18:741-747.
21. Gornet JM, Couve S, Hassani Z, et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. *Aliment Pharmacol Ther*. 2003;18:175-181.
22. The NCCN/ASCO Management of Immunotherapy-Related Toxicities (Immune Checkpoint Inhibitor-Related Toxicities) Clinical Practice Guidelines in Oncology (Version 3.2021 – May 14, 2021). © 2021 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed September 24, 2021.
23. Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. *Arthritis Rheumatol*. 2019;71(6):846-863.
24. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. *Arthritis Rheum*. 2013;65(10):2499-2512.
25. Dabade TS, Davis MD. Diagnosis and treatment of the neutrophilic dermatoses (pyoderma gangrenosum, Sweet's syndrome). *Dermatol Ther*. 2011;24(2):273-284.
26. Amin EN, Closser DR, Crouser ED. Current best practice in the management of pulmonary and systemic sarcoidosis. *Thor Adv Respir Dis*. 2014;8(4):111-132.
27. Riera E, Olivé A, Narváez J, et al. Adult onset Still's disease: review of 41 cases. *Clin Exp Rheumatol*. 2011;29(2):331-336.
28. Pouchot J, Arlet JB. Biological treatment in adult-onset Still's disease. *Best Pract Res Clin Rheumatol*. 2012;26(4):477-487.
29. Kontzias A, Efthimiou P. Adult-onset Still's disease: pathogenesis, clinical manifestations and therapeutic advances. *Drugs*. 2008;68:319-337.
30. Dastmalchi, M, Grundtman, C, Alexanderson, H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. *Ann Rheum Dis*. 2008;67:1670-1677.
31. Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. *Ann Rheum Dis*. 2020;79(1):19-30.

## HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	<b>Crohn's Disease:</b> Examples of biologics were moved to be included in the Appendix (previously listed in a Note in the criteria section). For the criterion applying to previous therapy, wording was changed to specify this must have been a conventional systemic	09/23/2020

	<p>therapy (criteria previously required a trial of one other agent, with conventional systemic agents listed among the examples).</p> <p><b>Plaque Psoriasis:</b> Examples of biologics were moved to be included in the Appendix (previously listed in a Note in the criteria section).</p> <p><b>Rheumatoid Arthritis:</b> Examples of biologics were moved to be included in the Appendix (previously listed in a Note in the criteria section).</p> <p><b>Ulcerative Colitis:</b> Examples of biologics were moved to be included in the Appendix (previously listed in a Note in the criteria section).</p> <p><b>Graft Versus Host Disease (GVHD):</b> To align with updated NCCN guidelines and other policies, criteria were changed to require at least one conventional systemic treatment prior to an infliximab product. Previously, criteria required that the patient had tried at least one other immunosuppressant or be concurrently receiving an immunosuppressant in combination with an infliximab product.</p> <p><b>Juvenile Idiopathic Arthritis:</b> Examples of biologics were moved to be included in the Appendix (previously listed in a Note in the criteria section).</p>	
Annual Revision	<p><b>Juvenile Idiopathic Arthritis:</b> The approval condition was reworded to as listed. Previously the indication also included Juvenile Rheumatoid Arthritis (regardless of type of onset), which was moved into a Note.</p> <p><b>Immunotherapy-Related Toxicities Associated with Checkpoint Inhibitor Therapy:</b> The requirement that the patient has an immunotherapy-related toxicity was reworded to generally refer to an immunotherapy-related toxicity other than hepatitis. Specific toxicities related to the gastrointestinal system, inflammatory arthritis, and ocular toxicity were moved from the criteria into a note representing examples of various immunotherapy-related toxicities.</p> <p><b>Uveitis:</b> The approval condition was reworded to as listed. Previously, the indication included other posterior uveitides and panuveitis syndromes, which was moved into a note.</p>	09/29/2021
Selected Revision	<p>Infliximab intravenous infusion (authorized generic to Remicade) was added to the policy. Criteria are the same as the other infliximab products addressed in the policy.</p>	12/08/2021

**APPENDIX**

<b>Product</b>	<b>Mechanism of Action</b>	<b>Examples of Inflammatory Indications for Products*</b>
<b>Biologics</b>		
<b>Adalimumab SC Products</b> (Humira <sup>®</sup> , biosimilars)	Inhibition of TNF	AS, CD, JIA, PsO, PsA, RA, UC
<b>Cimzia<sup>®</sup></b> (certolizumab pegol SC injection)	Inhibition of TNF	AS, CD, nr-axSpA, PsO, PsA, RA
<b>Etanercept SC Products</b> (Enbrel <sup>®</sup> , biosimilars)	Inhibition of TNF	AS, JIA, PsO, PsA
<b>Infliximab IV Products</b> (Remicade <sup>®</sup> , biosimilars)	Inhibition of TNF	AS, CD, PsO, PsA, RA, UC
<b>Simponi<sup>®</sup>, Simponi<sup>®</sup> Aria<sup>™</sup></b> (golimumab SC injection, golimumab IV infusion)	Inhibition of TNF	SC formulation: AS, PsA, RA, UC
		IV formulation: AS, PsA, RA
<b>Actemra<sup>®</sup></b> (tocilizumab IV infusion, tocilizumab SC injection)	Inhibition of IL-6	SC formulation: PJIA, RA, SJIA
		IV formulation: PJIA, RA, SJIA
<b>Kezvara<sup>®</sup></b> (sarilumab SC injection)	Inhibition of IL-6	RA
<b>Orencia<sup>®</sup></b> (abatacept IV infusion, abatacept SC injection)	T-cell costimulation modulator	SC formulation: JIA, PSA, RA
		IV formulation: JIA, PsA, RA
<b>Rituximab IV Products</b> (Rituxan <sup>®</sup> , biosimilars)	CD20-directed cytolytic antibody	RA
<b>Kineret<sup>®</sup></b> (anakinra SC injection)	Inhibition of IL-1	JIA <sup>^</sup> , RA
<b>Stelara<sup>®</sup></b> (ustekinumab SC injection, ustekinumab IV infusion)	Inhibition of IL-12/23	SC formulation: CD, PsO, PsA, UC
		IV formulation: CD, UC
<b>Siliq<sup>™</sup></b> (brodalumab SC injection)	Inhibition of IL-17	PsO
<b>Cosentyx<sup>™</sup></b> (secukinumab SC injection)	Inhibition of IL-17A	AS, nr-axSpA, PsO, PsA
<b>Taltz<sup>®</sup></b> (ixekizumab SC injection)	Inhibition of IL-17A	AS, nr-axSpA, PsO, PsA
<b>Ilumya<sup>™</sup></b> (tildrakizumab-asmm SC injection)	Inhibition of IL-23	PsO
<b>Skyrizi<sup>™</sup></b> (risankizumab-rzza SC injection)	Inhibition of IL-23	PsO
<b>Tremfya<sup>™</sup></b> (guselkumab SC injection)	Inhibition of IL-23	PsO, PsA
<b>Entyvio<sup>™</sup></b> (vedolizumab IV infusion)	Integrin receptor antagonist	CD, UC
<b>Targeted Synthetic DMARDs</b>		
<b>Otezla<sup>®</sup></b> (apremilast tablets)	Inhibition of PDE4	PsO, PsA
<b>Olumiant<sup>®</sup></b> (baricitinib tablets)	Inhibition of the JAK pathways	RA
<b>Rinvoq<sup>®</sup></b> (upadacitinib extended-release tablets)	Inhibition of the JAK pathways	RA
<b>Xeljanz<sup>®</sup>, Xeljanz XR</b> (tofacitinib tablets, tofacitinib extended-release tablets)	Inhibition of the JAK pathways	RA, PsA, UC

\* Not an all-inclusive list of indication (e.g., oncology indications and rare inflammatory conditions are not listed). Refer to the prescribing information for the respective agent for FDA-approved indications; SC – Subcutaneous; TNF – Tumor necrosis factor; IV – Intravenous, IL – Interleukin; PDE4 – Phosphodiesterase 4; JAK – Janus kinase; AS – Ankylosing spondylitis; CD – Crohn’s disease; JIA – Juvenile idiopathic arthritis; PsO – Plaque psoriasis; PsA – Psoriatic arthritis; RA – Rheumatoid arthritis; UC – Ulcerative colitis; nr-axSpA – Non-radiographic axial spondyloarthritis; ^ Off-label use of Kineret in JIA supported in guidelines.